PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28598078-13	2016	The transmission of KPC-2 plasmid in Klebsiella oxytoca may cause imipenem resistance in Klebsiella pneumonia.	Imipenem	66-74	carbapenem-hydrolyzing beta-lactamase KPC-2	Klebsiella pneumoniae	20-25	
20564966-7	2010	All the isolates were also shown to harbour the bla(KPC) gene by PCR with primers targeting the core 372 bp fragment of the gene, and all but two were resistant to imipenem and meropenem as determined by the disc-diffusion method.	Imipenem	164-172	carbapenem-hydrolyzing beta-lactamase KPC-2	Klebsiella pneumoniae	52-55	
23128404-3	2013	The enzyme, Klebsiella pneumoniae carbapenemase (KPC)-2, was detected in all four isolates and this was the main cause of their imipenem resistance.	Imipenem	128-136	carbapenem-hydrolyzing beta-lactamase KPC-2	Klebsiella pneumoniae	12-55	
22330927-4	2012	To illustrate our approach, MK-7655 was used in combination with imipenem against a clinical isolate of Klebsiella pneumoniae known to produce KPC-2.	Imipenem	65-73	carbapenem-hydrolyzing beta-lactamase KPC-2	Klebsiella pneumoniae	143-148	
22016687-5	2011	The KPC-2-producing isolate was resistant to all tested beta-lactams (including imipenem and meropenem), amikacin, tobramycin, ciprofloxacin, levofloxacin, and trimethoprim-sulfamethoxazole, but was susceptible to gentamicin, colistin, polymyxin B, and tigecycline.	Imipenem	80-88	carbapenem-hydrolyzing beta-lactamase KPC-2	Klebsiella pneumoniae	4-9	
35309213-9	2022	Ceftazidime and imipenem by combining avibactam (4 mug/mL) significantly decreased the MIC90 values more than 16-fold than ceftazidime and imipenem alone against Klebsiella pneumoniae carbapenemase (KPC)-2-producing K. pneumoniae.	Imipenem	16-24	carbapenem-hydrolyzing beta-lactamase KPC-2	Klebsiella pneumoniae	162-205	
34630354-6	2021	However, the restored carbapenem susceptibility in vivo was not stable and the subsequent use of imipenem against KPC-33-producing K. pneumoniae infection resulted in a reversion of KPC-2 producers (ZRKP03 and ZRKP04, ceftazidime-avibactam-S/carbapenem-R).	Imipenem	97-105	carbapenem-hydrolyzing beta-lactamase KPC-2	Klebsiella pneumoniae	182-187	
35311523-4	2022	Using timed mass spectrometry, the D179Y variant formed prolonged acyl-enzyme complexes with imipenem (IMI) and meropenem (MEM) in KPC-2 and KPC-3, which could be detected up to 24 h, suggesting that IMI and MEM act as covalent beta-lactamase inhibitors more than as substrates for D179Y KPC-2 and -3.	Imipenem	93-101	carbapenem-hydrolyzing beta-lactamase KPC-2	Klebsiella pneumoniae	131-136	
35311523-4	2022	Using timed mass spectrometry, the D179Y variant formed prolonged acyl-enzyme complexes with imipenem (IMI) and meropenem (MEM) in KPC-2 and KPC-3, which could be detected up to 24 h, suggesting that IMI and MEM act as covalent beta-lactamase inhibitors more than as substrates for D179Y KPC-2 and -3.	Imipenem	93-101	carbapenem-hydrolyzing beta-lactamase KPC-2	Klebsiella pneumoniae	288-300	
35311523-4	2022	Using timed mass spectrometry, the D179Y variant formed prolonged acyl-enzyme complexes with imipenem (IMI) and meropenem (MEM) in KPC-2 and KPC-3, which could be detected up to 24 h, suggesting that IMI and MEM act as covalent beta-lactamase inhibitors more than as substrates for D179Y KPC-2 and -3.	Imipenem	103-106	carbapenem-hydrolyzing beta-lactamase KPC-2	Klebsiella pneumoniae	131-136	
35311523-4	2022	Using timed mass spectrometry, the D179Y variant formed prolonged acyl-enzyme complexes with imipenem (IMI) and meropenem (MEM) in KPC-2 and KPC-3, which could be detected up to 24 h, suggesting that IMI and MEM act as covalent beta-lactamase inhibitors more than as substrates for D179Y KPC-2 and -3.	Imipenem	103-106	carbapenem-hydrolyzing beta-lactamase KPC-2	Klebsiella pneumoniae	288-300	
12615876-3	2003	The KPC-2-producing isolates were either susceptible or intermediate to imipenem and meropenem, unlike the KPC-1-producing isolate, which was resistant to these agents.	Imipenem	72-80	carbapenem-hydrolyzing beta-lactamase KPC-2	Klebsiella pneumoniae	4-9	
35309213-9	2022	Ceftazidime and imipenem by combining avibactam (4 mug/mL) significantly decreased the MIC90 values more than 16-fold than ceftazidime and imipenem alone against Klebsiella pneumoniae carbapenemase (KPC)-2-producing K. pneumoniae.	Imipenem	139-147	carbapenem-hydrolyzing beta-lactamase KPC-2	Klebsiella pneumoniae	162-205	
27469416-8	2017	A total of 121 isolates were resistant to imipenem, of which 104 (86%) produced carbapenemases: 74 OXA-48, 14 VIM, 9 KPC (6 KPC-2 and 3 KPC-3), 6 IMP, and 1 GES.	Imipenem	42-50	carbapenem-hydrolyzing beta-lactamase KPC-2	Klebsiella pneumoniae	124-135	
32464197-6	2020	MICs of imipenem and meropenem against LysM clone were increased by several folds as compared to NP-6 clinical strain as well as DH5 alpha (PET-28a KPC-2) clone.	Imipenem	8-16	carbapenem-hydrolyzing beta-lactamase KPC-2	Klebsiella pneumoniae	148-153	
30632921-5	2019	Secretion of KPC-2 and its variant KPC-3 by the K. pneumoniae strains causes resistance to both the substrate imipenem and the beta-lactamase inhibitors.	Imipenem	110-118	carbapenem-hydrolyzing beta-lactamase KPC-2	Klebsiella pneumoniae	13-18